Clinical Trial Update: CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria [Phase 3]

View source ↗

Summary

Phase 3 trial comparing CSE-1034 (ceftriaxone+ sulbactam+ EDTA) versus meropenem in complicated urinary tract infections due to ESBL-producing Gram-negative bac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pyelonephritis
• Urinary Tract Infection

Drugs mentioned

• CSE-1034 (ceftriaxone+ sulbactam+ EDTA)
• Meropenem (Meropenem)

Snippet

Sponsor: Venus Remedies Limited | Conditions: Urinary Tract Infection Complicated, Acute Pyelonephritis | Phase 3 | Status: COMPLETED